Passage Bio Statistics
Want to see PASG full AI Analyst Report?
Passage Bio (PASG) Stock Statistics & Valuation Metrics
Total Valuation
Passage Bio has a market cap or net worth of $13.68M. The enterprise value is -$5.68M.
- Market Cap
- $13.68M
- Enterprise Value
- -$5.68M
Share Statistics
Passage Bio has 3,217,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,217,810
- Owned by Insiders
- 21.90%
- Owned by Institutions
- 14.57%
Financial Efficiency
Passage Bio’s return on equity (ROE) is -2.43 and return on invested capital (ROIC) is -100.90%.
- Return on Equity (ROE)
- -2.43
- Return on Assets (ROA)
- -0.73
- Return on Invested Capital (ROIC)
- -100.90%
- Return on Capital Employed (ROCE)
- -1.10
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.90M
- Employee Count
- 24
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Passage Bio is -0.41. Passage Bio’s PEG ratio is -0.01.
- PE Ratio
- -0.41
- PS Ratio
- 0.00
- PB Ratio
- 273.51
- Price to FCF
- -0.42
- Price to Operating Cash Flow
- -0.42
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Passage Bio had revenue of 0 and earned -45.52M in profits. Earnings per share was -14.35.
- Revenue
- 0
- Gross Profit
- -728.00K
- Operating Income
- -43.15M
- Pretax Income
- -45.52M
- Net Income
- -45.52M
- EBITDA
- -44.79M
- Earnings Per Share (EPS)
- -14.35
Cash Flow
In the last 12 months, operating cash flow was -32.65M and capital expenditures 0, giving a free cash flow of -32.65M billion.
- Operating Cash Flow
- -32.65M
- Free Cash Flow
- -32.65M
- Free Cash Flow per Share
- -10.15
Dividends & Yields
Passage Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -238.71%
- Earnings Yield
- -241.90%
Stock Price Statistics
- Beta
- 2.25
- 52-Week Price Change
- -50.18%
- 50-Day Moving Average
- 4.12
- 200-Day Moving Average
- 5.75
- Relative Strength Index (RSI)
- 59.75
- Average Volume (3m)
- 21.01K
Important Dates
Passage Bio upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Jul 30, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Passage Bio as a current ratio of 2.07, with Debt / Equity ratio of 128.02%
- Current Ratio
- 2.07
- Quick Ratio
- 2.07
- Debt to Market Cap
- 0.55
- Net Debt to EBITDA
- 0.50
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Passage Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Passage Bio EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.20.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.22
- EV to Free Cash Flow
- 0.20
- EV to Operating Cash Flow
- 0.20
Balance Sheet
Passage Bio has $20.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of $20.16M billion.
- Cash & Marketable Securities
- $20.16M
- Total Debt
- $0.00
- Net Cash
- $20.16M
- Net Cash Per Share
- $6.27
- Tangible Book Value Per Share
- $0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Passage Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 28.49%
Scores
- Smart Score
- ―
- AI Score
- 46

